| Scorecard |
|---|
|
3 / 5 Stars
|
|
Lipper
2
3
5
2
2
|
|
Zacks Investment Research
3
(Hold)
|
|
Standard & Poor's
3 / 5 Stars
|
|
TheStreet.com
A-
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 0.0 | 0.0 |
| Stocks | 87.31 | 87.31 |
| Bonds | 0.0 | 0.0 |
| Other | 0.0 | 0.0 |
| Foreign Bonds | 2.32 | 2.32 |
| Foreign Stocks | 10.36 | 10.36 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 03.31.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 03.31.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Pfizer Inc | PFE | 16.19 | 4.42 |
| Gilead Sciences Inc | GILD | 36.53 | 4.16 |
| Johnson & Johnson | JNJ | 21.03 | 3.94 |
| Amgen Inc | AMGN | 21.82 | 3.52 |
| Merck & Co Inc | MRK | 12.65 | 3.46 |
| Celgene Corporation | CELG | 48.67 | 2.9 |
| Eli Lilly and Company | LLY | 10.97 | 2.87 |
| Bristol-Myers Squibb Company | BMY | 24.03 | 2.4 |
| Central Cash Management Fd Central Cash Management Fd | --- | --- | 2.32 |
| UnitedHealth Group Inc | UNH | 10.5 | 2.27 |
